Opendata, web and dolomites

HITCHIPDIAG

Rapid and Inexpensive Diagnosis of Heparin Induced Thrombocytopenia Using Glycan Arrays Containing Synthetic Glycosaminoglycans

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 HITCHIPDIAG project word cloud

Explore the words cloud of the HITCHIPDIAG project. It provides you a very rough idea of what is the project "HITCHIPDIAG" about.

grant    maipa    hipa    structure    reduce    anticoagulant    acute    syndrome    model    patients    business    onto    microarray    complications    rapid    assembly    reliabilities    cardiopulmonary    surgery    detected    wellbeing    synthetic    glycosaminoglycan    specificity    dialysis    deep    carbohydrate    platelet    strategy    annually    blood    thrombosis    company    gag    cheaper    surfaces    standard    tests    markers    glycan    space    accuracy    million    thrombocytopenia    commercial    erc    mortality    plan    20    effect    develops    twelve    vein    bypass    inexpensive    instrument    prepare    diagnostics    suffer    diagnose    oligosaccharides    investors    administration    diagnostic    heparin    faster    microarrays    screen    markets    adverse    hit    autoheparin    basis    yielded    antibodies    diagnosis    coronary    customers    glycosaminoglycans    dangerous    infarction    detect    commercialize    discovered    patient    organ    protocols    arrays    containing    minutes    incorporate    ip    printing    automated   

Project "HITCHIPDIAG" data sheet

The following table provides information about the project.

Coordinator
MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV 

Organization address
address: HOFGARTENSTRASSE 8
city: MUENCHEN
postcode: 80539
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 147˙094 €
 EC max contribution 147˙094 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2014-PoC
 Funding Scheme ERC-POC
 Starting year 2015
 Duration (year-month-day) from 2015-04-01   to  2016-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV DE (MUENCHEN) coordinator 147˙094.00

Map

 Project objective

Rapid and Inexpensive Diagnosis of Heparin Induced Thrombocytopenia Using Glycan Arrays Containing Synthetic Glycosaminoglycans Heparin, a complex glycosaminoglycan (GAG) carbohydrate, is the most commonly used anticoagulant. Twelve million patients in the EU are treated annually for conditions including acute coronary syndrome, deep-vein thrombosis and cardiopulmonary bypass surgery. Heparin-induced thrombocytopenia (HIT) is a dangerous adverse side effect of heparin administration. HIT-II develops after major surgery or dialysis and results in infarction, multi-organ failure and 20% mortality. In Europe 100,000 patients develop HIT-II annually. Currently, two HIT-II diagnostics are available. The HIPA and MAIPA tests detect antibodies against a complex of heparin and platelet factor 4 but suffer from low diagnostic specificity and accuracy. Faster, more reliable and cheaper methods to diagnose complications after administration of heparin are needed to improve patient wellbeing and reduce costs. The ERC Advanced grant AUTOHEPARIN yielded an instrument for the automated assembly of defined oligosaccharides. GAG glycan microarrays were produced by printing GAG oligosaccharides onto surfaces and used to screen patient blood. Specific glycan markers of high diagnostic value were discovered to detected HIT-II within minutes and reliabilities well above existing tests. The overall goal of the project is to establish the business model for a company that will focus on the production of GAG glycan arrays as HIT diagnostic. Specific activities include: 1) Development of standard protocols to detect HIT-II using GAG glycan microarray; 2) Plan and cost structure for GAG arrays production; 3) Analysis of the IP space and development of an IP strategy; 4) Evaluate potential markets and establish basis for commercial discussion with potential customers; 5) Prepare business plan for discussions with investors; 6) Incorporate company to commercialize GAG arrays as HIT diagnostic

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HITCHIPDIAG" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HITCHIPDIAG" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

evolSingleCellGRN (2019)

Constraint, Adaptation, and Heterogeneity: Genomic and single-cell approaches to understanding the evolution of developmental gene regulatory networks

Read More  

IMMUNOTHROMBOSIS (2019)

Cross-talk between platelets and immunity - implications for host homeostasis and defense

Read More  

RODRESET (2019)

Development of novel optogenetic approaches for improving vision in macular degeneration

Read More